List view / Grid view
5 September 2013 | By GlaxoSmithKline
In line with the Independent Data Monitoring Committee’s unanimous recommendation, GSK will continue the DERMA trial until the second co-primary endpoint is assessed...
4 September 2013 | By Merck
Merck has received approval from the U.S. FDA to manufacture bulk varicella at the company’s site in Durham...
4 September 2013 | By Novartis
Novartis reaffirms continued innovation in transplant during anniversary year of breakthrough therapy, ciclosporin...
4 September 2013 | By AstraZeneca
As a result of the initiation of this programme, a pre-tax impairment charge of $285 million will be reversed and the asset restored to our balance sheet in the third quarter of 2013...
4 September 2013 | By Abbott
Abbott announced promising preliminary results from a study presented at the ESC Congress 2013...
4 September 2013 | By Novartis
Robust efficacy of once-daily Ultibro® Breezhaler® (QVA149) supported by a pooled analysis of the Phase III IGNITE clinical trial program further strengthens evidence for the Ultibro® LABA+LAMA combination for the treatment of COPD patients[1],[2],[3]...
3 September 2013 | By Sanofi
Prequalification makes the vaccine eligible for purchase by United Nations Agencies...
3 September 2013 | By Novartis
Ilaris® is the first interleukin-1 beta (IL-1 beta) inhibitor for the treatment of Systemic Juvenile Idiopathic Arthritis (SJIA) and is the only treatment approved specifically for SJIA that is given as a monthly subcutaneous injection[1]...
3 September 2013 | By Boehringer Ingelheim
Boehringer Ingelheim announces new plans to expand body of evidence for Pradaxa®...
3 September 2013 | By Amgen
First trial to evaluate cardiac myosin activator in patients with acute heart failure presented at ESC Congress 2013...
3 September 2013 | By O2PR LTD
Selcia Limited has entered into a drug discovery collaboration with Cantab Anti-Infectives...
3 September 2013 | By Johnson & Johnson
“We’re proud of our work on siltuximab. As a rare disease with a small patient population, MCD is an area of significant unmet need”
3 September 2013 | By Pfizer
Data show consistent results in reductions in stroke or systemic embolism, fewer major bleeding events, and reductions in all-cause death...
2 September 2013 | By Novartis
New analysis of RELAX-AHF published in the European Heart Journal and presented as a late breaker at the European Society of Cardiology congress[1],[2]...
2 September 2013 | By GlaxoSmithKline
GSK announced that the European Commission has granted marketing authorisation for Tafinlar™ (dabrafenib)...
